Records containing: Invasive Breast Carcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-01-22Metformin (Dimethylbiguanide) and Insulin Resistance in Women Completing Neoadjuvant and/or Adjuvant Cytotoxic Treatment of Stage I-III Breast Cancer
-
CLINICAL_TRIALS study record update · 2026-01-08Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter Pylori Neutrophil-Activating Protein (NAP) (MV-s-NAP) in Patients With Metastatic Breast Cancer
-
CLINICAL_TRIALS study record update · 2026-01-07Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer
-
CLINICAL_TRIALS study record update · 2026-01-06Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Inflammatory Breast Cancer: a Prospective Trial
-
CLINICAL_TRIALS study record update · 2026-01-05Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A Randomized, Phase IIb, Window of Opportunity Presurgical Trial.
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-12-17Assessing the Cosmesis and Toxicity of Partial Breast Irradiation Using Proton Beam Irradiation
-
CLINICAL_TRIALS study record update · 2025-12-04A Comprehensive Breast Cancer Survivorship Biorepository
-
CLINICAL_TRIALS study record update · 2025-11-12Window Trial of Abemaciclib for Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer (a BEAUTY Study*)
-
CLINICAL_TRIALS study record update · 2025-11-10Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)
-
CLINICAL_TRIALS study record update · 2025-11-10A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-10-29The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
-
CLINICAL_TRIALS study record update · 2025-10-27Potential Impact of the COVID -19 Pandemic on Financial Toxicity in Breast Cancer Surgical Patients: The Impact on Out of Pocket Costs, Lost Wages and Economic Strain
-
CLINICAL_TRIALS study record update · 2025-10-09A Phase II Study of the Determinants of Transdermal Drug Delivery to the Normal and the Radiated Breast
-
CLINICAL_TRIALS study record update · 2025-09-17Added Value of Contrast Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion to a Tertiary Cancer Center
-
CLINICAL_TRIALS study record update · 2025-09-08Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
-
CLINICAL_TRIALS study record update · 2025-08-22ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
-
CLINICAL_TRIALS study record update · 2025-08-01Time Restricted Eating for Patients With HER2- Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
-
CLINICAL_TRIALS study record update · 2025-08-01ARTEMIS: A Robust TNBC Evaluation FraMework to Improve Survival
-
CLINICAL_TRIALS study record update · 2025-07-03Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)
-
CLINICAL_TRIALS study record update · 2025-06-15Comprehensive Single-Cell Transcriptional Analysis of Aromatase Inhibitor-Resistant Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-05-23A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-05-22A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
-
CLINICAL_TRIALS study record update · 2025-05-21A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-05-13A Phase 1B Trial Evaluating the Safety of Ribociclib, Tucatinib, and Trastuzumab in Patients With Metastatic, HER2+ Breast Cancer and a Multicenter, Randomized, Open-Label, Phase 2 Study of Preoperative Treatment With Ribociclib,Ttrastuzumab, Tucatinib, and Fulvestrant Versus Docetaxel, Carboplatin,Ttrastuzumab, and Pertuzumab in HR+/HER2+ Breast Cancer and Ribociclib, Trastuzumab, and Tucatinib Versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients With HR-/HER2+ Breast Cancer
-
CLINICAL_TRIALS study record update · 2025-04-24A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases